# Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

> **NCT05742425** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Unresectable Colon Cancer Peritoneal Metastases
- PMMR/Ras/BRAF Wild-type

## Interventions

- **DRUG:** Serplulimab Combined With FOLFIRI and Bevacizumab

## Key facts

- **NCT ID:** NCT05742425
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742425, "Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05742425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*